CMHC 2015 Symposium: Diagnosis and Management Strategies for Lipodystrophy
Novel therapies, including the FDA-approved leptin replacement therapy, have been shown to reduce the metabolic consequences of some subtypes of lipodystrophy. This webcast, endorsed by Lipodystrophy United, is framed around case studies that introduce, highlight, and/or reinforce key presentation and discussion topics related to lipodystrophy, including its metabolic consequences and the impact of these consequences on long-term outcomes.
Supported by an educational grant from Aegerion Pharmaceuticals, Inc.
Endorsed by Lipodystrophy United.
CMHC 2015 Symposium: Diagnosis and Management Strategies for Lipodystrophy
Activity Title: The Faces of Lipodystrophy: Contemporary Diagnosis and Management Strategies for an Unrecognized Cardiometabolic Disorder
Activity Format: Video Webcast
Estimated Time to Complete: 1.75 hours
Release Date: December 21, 2015
Expiration Date: December 21, 2016
Credit Type(s) Available: ACCME, CDR, ANCC
Maximum Credits: 1.75 AMA PRA Category 1 Credit(s)TM
Provided By: This activity is jointly provided by HealthScience Media, Inc. (HSM) and Medical Education Resources, Inc (MER).
This activity is supported by an educational grant from Aegerion Pharmaceuticals, Inc. Endorsed by Lipodystrophy United.
Lipodystrophy is a group of rare syndromes characterized by selective loss of adipose tissue from various parts of the body. Novel therapies, including the FDA-approved leptin replacement therapy, have been shown to reduce the metabolic consequences of some subtypes of lipodystrophy. This webcast, endorsed by Lipodystrophy United, is framed around case studies that introduce, highlight, and/or reinforce key presentation and discussion topics related to lipodystrophy, including its metabolic consequences and the impact of these consequences on long-term outcomes. Expert faculty, along with a lipodystrophy patient advocate, put a face to the disease and educate the audience on the importance of early recognition and treatment.
To improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.
This activity is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk.
Upon completion of this activity, participants should be able to:
Differentially diagnose various types of lipodystrophy based on the degree and pattern of adipose tissue loss, other clinical features, and appropriate laboratory testing.
Describe the etiologic causes and pathophysiologic mechanisms of congenital and acquired lipodystrophies.
Identify the limitations of traditional therapies that are commonly used to treat the metabolic consequences associated with lipodystrophy.
Evaluate evidence supporting pharmacologic treatment of lipodystrophy and associated metabolic disorders.
List the psychosocial implications lipodystrophy can have on patients.
Abhimanyu Garg, MD
Professor of Internal Medicine
Chief, Division of Nutrition and Metabolic Diseases
UT Southwestern Medical Center
Disclosures: Grants/Research Support: Pfizer Consulting Fees: Tekmira, Health Advances, AstraZeneca, Amgen, Back Bay Life Sciences, Biomarin Pharmaceuticals, Gerson Lehrman Group, Engage Health, Ipsen Pharmaceuticals, Medscape, Intellisphere, LLC
Elaine K. Cochran, CRNP
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Diabetes, Endocrinology and Obesity Branch
Ms. Cochran has nothing to disclose.
Vinaya Simha, MBBS, MD
Assistant Professor of Medicine
Mayo Clinic College of Medicine
Dr. Simha has nothing to disclose.
Dwanna Swan, PhD
Dr. Swan has nothing to disclose.
Disclosure of Conflicts of Interest:
It is the policy of MER to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The following content managers reported no financial relationships with commercial interests whose products or services may be mentioned in this CME/CE activity:
MER: Julie Johnson, PharmD, Stephen Scharmann, MD, Veronda Smith, FNP
HSM: Karin McAdams, Mary Mihalovic, Nicola Sirdevan, Melissa Wiles
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates each enduring material for a maximum of 1.75 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Each CE activity provides 1.75 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.75 contact hours per activity.
Medical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of each program/material.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER, HSM and/or the various industry supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, HSM, and/or the various industry supporters. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Viewers are expected to view all presentations that are part of an activity before attempting to complete the post-test and evaluation for that activity. Successful completion will lead to the issuance of a certificate for 1.75 AMA PRA Category 1 Credit(s)™.
To receive credit, the course must be completed before December 21, 2016.
If you attended the live presentation on October 21 - 24, 2015 in Boston, MA and have received CME credit for this program, you are not eligible for additional credit.
There are no fees for participating in and receiving CME credit for this activity. In order to claim CME credit for this activity registration is required prior to viewing the activity.
During the period December 21, 2015 through December 21 2016, participants must follow these steps in order to receive CME/CE credit:
Sign In or Register.
Read and accept the Terms & Conditions including the learning objectives and faculty disclosures.
Complete the pre-test by recording the best answer to each question in the answer key. There is no scoring of the pre-test questions section.
View and study all presentations that are part of the educational activity.
Complete the post-test by recording the best answer to each question in the answer key. Successful completion of the post-test is required to earn CME/CE credit. Successful completion is defined as a cumulative score of at least 70%.
Complete the online evaluation form.
After successfully completing the post-test and online evaluation form, your CME/CE certificate will be generated and will be available immediately for print.
Hardware and Software Requirements:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
Policy on Privacy and Confidentiality:
MER can be contacted by e-mail at firstname.lastname@example.org or by telephone at 303-798-9682.
Please check the agreement box before continuing.
I have read the information above and agree to continue with this program.